Emyria

Mental health is one of our fastest-growing global healthcare challenges, demanding entirely new solutions. At Emyria, we are leading the way by actively evaluating MDMA- and psilocybin-assisted therapies to treat PTSD and treatment-resistant depression, aiming to significantly improve patient outcomes.

<b>Our approach is twofold:</b>

1) First, our clinics are designed as world-class learning environments where we rigorously test and refine these models so they can scale and deliver significant patient impact today.

2) Second, we leverage our critical patient data to advance a proprietary innovation pipeline of MDMA-inspired medicines and new treatment approaches. We're targeting the next generation of drug assisted therapies as well as select neurological conditions to set the foundation for a new era in mental healthcare.


Emyria’s purpose is to optimise patient outcomes and experiences. Operating as a publicly listed entity, we are acutely aware of, and embrace, the heightened scrutiny associated with our work, which involves measuring the effectiveness of new medical treatments to improve the lives of vulnerable patients on the frontline.

Appreciating the sensitivity of our work, Emyria operates within a stringent clinical governance framework that includes ethics-endorsed care models, a clear code of conduct and values policy for all clinicians, comprehensive data governance and privacy policies. This includes an active risk management program that ensures continuous learning and improvement.
	
Emyria’s complaint handling process supports anyone wishing to raise a concern. We allow individuals to come forward anonymously and provide all necessary assistance throughout. These practices and philosophies guide our efforts to deliver and develop new treatments for mental health and are part of our pledge to promote transparency, uphold professional conduct, and continuously improve – ensuring our patients’ trust and health are always top of mind.




Interested in investing with Emyria?

News & Updates